XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 35 mg twice daily Xanamem™ in Subjects with mild dementia due to Alzheimer’s Disease (AD).
DEMENTIA TRIALS AUSTRALIA
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 35 mg twice daily Xanamem™ in Subjects with mild dementia due to Alzheimer’s Disease (AD).